ISDT

BD, Magnolia Medical Technologies Announce Commercial Collaboration to Help Reduce Blood Culture Contamination and Improve Testing Accuracy

Retrieved on: 
Tuesday, October 18, 2022
ZERO, LinkedIn, CDC, Disease, Therapy, Efficiency, BDX, Organization, Laboratory, NYSE, ISDT, Patient, Hospital, Blood culture, Twitter, Collection, Clinical, Centers for Disease Control and Prevention, Solution, Goal, Antimicrobial stewardship, Company, Sepsis, Becton, Dickinson and Company headquarters, Health, Blood, CEO, Awareness, Clinical and Laboratory Standards Institute, Patent, Becton, Safety, Vancomycin, CLSI, Intellectual property, Death, FDA, BD, Pharmaceutical industry, Medical device

FRANKLIN LAKES, N.J., Oct. 18, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Magnolia Medical Technologies, Inc., today announced a co-exclusive commercial agreement aimed at helping U.S. hospitals reduce blood culture contamination to help improve testing accuracy and ultimately improve clinical outcomes.

Key Points: 
  • FRANKLIN LAKES, N.J., Oct. 18, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Magnolia Medical Technologies, Inc., today announced a co-exclusive commercial agreement aimed at helping U.S. hospitals reduce blood culture contamination to help improve testing accuracy and ultimately improve clinical outcomes.
  • Reducing blood culture contamination can help improve testing accuracy and ultimately improve clinical outcomes and may lessen the threat of antibiotic resistance by giving health care practitioners more specific, reliable results."
  • Magnolia Medical Technologies develops, manufactures, and markets innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency, and predictability of critical laboratory tests.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Initial Specimen Diversion Device (ISDD) for blood culture collection and contamination prevention.

Magnolia Medical Technologies Files for Permanent Injunction Against Infringing Kurin Lock Products

Retrieved on: 
Tuesday, September 13, 2022
Kurin, ICHE, ENA, Infection, Antimicrobial, Good clinical laboratory practice, Clinical and Laboratory Standards Institute, Sale, FDA, Sepsis, Douglas v. U.S. District Court ex rel Talk America, ISDT, Magnolia, Intellectual property, INS, Confusion, Invention, Patient, District, CEO, CLSI, Technology, CDC, Laboratory, Patent, Clinical Laboratory, Collection, Blood culture, Vancomycin, District court, Hospital, Multimedia, Bloodstream infections, Online gambling, Pharmaceutical industry, Vaccine, Medical device

SEATTLE, Sept 13, 2022 /PRNewswire/ -- Magnolia Medical Technologies, Inc. ("Magnolia Medical"), inventors of the Steripath Initial Specimen Diversion Device (ISDD) family of products, today announced it filed a motion for permanent injunction in the U.S. District Court for the District of Delaware on September 9, 2022, that would prohibit Kurin, Inc. ("Kurin") from the continued sale of the infringing Kurin Lock products.

Key Points: 
  • SEATTLE, Sept 13, 2022 /PRNewswire/ -- Magnolia Medical Technologies, Inc. ("Magnolia Medical"), inventors of the Steripath Initial Specimen Diversion Device (ISDD) family of products, today announced it filed a motion for permanent injunction in the U.S. District Court for the District of Delaware on September 9, 2022, that would prohibit Kurin, Inc. ("Kurin") from the continued sale of the infringing Kurin Lock products.
  • The second verdict rejected Kurin's attempts to invalidate the asserted claims and awarded significant damages for the sale of the infringing Kurin Lock product, including a 17.7% royalty.
  • "We have made no agreement with Kurin that would permit Kurin to continue selling its infringing Kurin Lock.
  • Magnolia Medical Technologies develops, manufactures, and markets innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency, and predictability of critical laboratory tests.

Magnolia Medical's Steripath® Initial Specimen Diversion Device® Only Device Clinically Proven to Meet CDC's New Guidelines to Reduce Blood Culture Contamination

Retrieved on: 
Tuesday, August 23, 2022
Guideline, CEO, Technology, Good clinical laboratory practice, Laboratory, Awareness, Solution, Antimicrobial, Clinical Laboratory, Infection, Clinical and Laboratory Standards Institute, Blood culture, Blood, Collection, Vancomycin, CLSI, Procedure, Bloodstream infections, Education, Hospital, Patent, Multimedia, Journal of Hospital Medicine, Center, FDA, Centers for Disease Control and Prevention timeline, ICHE, Sepsis, ISDT, Magnolia, M47, Intellectual property, CDC, Clinical, Health, Pharmaceutical industry, Medical device, Vaccine

SEATTLE, Aug. 23, 2022 /PRNewswire/ -- Magnolia Medical Technologies, Inc., commends the Center for Disease Control and Prevention (CDC) for releasing its new evidence-based guidelines, Blood Culture Contamination: An Overview for Infection Control and Antibiotic Stewardship Programs Working with the Clinical Laboratory. These guidelines support Magnolia Medical's Mission to ZERO® with the goal of eliminating sepsis misdiagnosis and are intended to aid hospitals and healthcare systems in designing and implementing proven practices and technologies that decrease blood culture contamination rates.

Key Points: 
  • Magnolia Medical's flagship product family, the SteripathInitial Specimen Diversion Device, isthe only FDA 510(k)-cleared device platform specifically indicated to reduce blood culture contamination.6Steripathdiverts and sequesters the initial 1.5 to 2.0 mL of blood prior to specimen collection.
  • The CDC Guidelines also provided eight evidence-based practices for reducing blood culture contamination rates, including the use of Initial Specimen Diversion Devicesthat divert the initial 1 to 2 mL of potentially contaminated blood prior to blood collection.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique(ISDT) and Initial Specimen Diversion Device(ISDD) for blood culture collection and contamination prevention.
  • Getting to zero: impact of a device to reduce blood culture contamination and false-positive central line-associated blood stream infections.

Magnolia Medical Technologies Wins Patent-Infringement Lawsuit against Kurin, Inc.

Retrieved on: 
Friday, July 29, 2022
View, Clostridioides difficile infection, Clinical Laboratory Improvement Amendments, Hospital, CEO, Intellectual property, Antimicrobial, Sepsis, Collection, Patent, ISDT, Multimedia, Approximation error, Technology, Infection, FDA, Method, Blood culture, CDI, District court, CDC, Douglas v. U.S. District Court ex rel Talk America, Entrepreneurship, Clinical Laboratory, Pharmaceutical industry, Medical device, Vaccine, Clostridioides

SEATTLE, July 29, 2022 /PRNewswire/ -- A jury for the U.S. District Court of Delaware delivered two unanimous verdicts this week in favor of Magnolia Medical Technologies, Inc. ("Magnolia Medical") in a lawsuit against Kurin, Inc., ("Kurin") regarding the unlawful use of its innovative Initial Specimen Diversion Device® (ISDD®) technology. After a two-phased trial and short deliberations, the jury confirmed that Kurin has used Magnolia Medical's patented technology, which is clinically proven to significantly reduce blood culture contamination, without the company's permission. The jury also validated Magnolia Medical's patented technology and awarded significant damages in their final verdict.

Key Points: 
  • "Magnolia Medical Technologies is gratified by the jury's unanimous verdicts in our favor this week, finding that Kurin, Inc. unlawfully used our innovative technology without permission," said Magnolia Medical's CEO and Co-Founder Greg Bullington.
  • Bullington concluded, "Magnolia Medical is deeply committed to our Mission toZERO, with the goal of eliminating sepsis misdiagnosis.
  • Magnolia Medical Technologies develops, manufactures, and markets innovative blood and bodily fluid collection devices to facilitate significant improvements in the accuracy, consistency, and predictability of critical laboratory tests.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Initial Specimen Diversion Device (ISDD) for blood culture collection and contamination prevention.

Magnolia Medical Launches New Company Website to Educate Healthcare Providers on Blood Culture Contamination and to Increase Awareness of the Devastating Impact of Sepsis Misdiagnosis

Retrieved on: 
Thursday, June 2, 2022
Health, Blood culture, Goal, Intellectual property, Sepsis, Patent, CEO, Sepsis Alliance, Environment, Awareness, Pain, Solution, Multimedia, Magnolia, Nursing, FDA, Patient, Hospital, Technology, Compliance, ISDT, Antimicrobial stewardship, ZERO, Collection, Engineering, Mission, Invention, Patient safety, Medical device, Medicine, Pharmaceutical industry

SEATTLE, June 2, 2022 /PRNewswire/ -- Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform specifically indicated to reduce blood culture contamination for sepsis testing accuracy,1 today announced the launch of its new website (www.magnolia-medical.com).

Key Points: 
  • For each person who signs the pledge to prevent sepsis misdiagnosis for better patient outcomes, Magnolia Medical will make a donation to Sepsis Alliance.
  • The website provides a streamlined user interface for improved navigation and has been designed to scale with Magnolia Medical's expanded educational offerings.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Initial Specimen Diversion Device (ISDD) for blood culture collection and contamination prevention.
  • Indicated to reduce the frequency of blood culture contamination when contaminants are present, compared to standard method controls without diversion.

Novel Study Demonstrates the Hospital-Wide Impact of the Steripath® Initial Specimen Diversion Device® on Blood Culture Contamination Rates and Sepsis Testing Accuracy at WVU Medicine - United Hospital Center

Retrieved on: 
Wednesday, April 6, 2022
ISDT, Magnolia, Laboratory, Blood culture, Infection, Invention, Nursing, Patent, Clinical, Intravenous therapy, Multimedia, Patient, American Journal, WVU Medicine, Quality, Procedure, University Health System, Hospital, CEO, American Journal of Medical Quality, Emergency, Sepsis, Goal, Vancomycin, Intellectual property, CLSI, Clinical and Laboratory Standards Institute, FDA, MedStar Washington Hospital Center, Collection, Pharmaceutical industry, Medical device

SEATTLE, April 6, 2022 /PRNewswire/ -- Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing accuracy,1 today announced the publication of results from a study performed by United Hospital Center, a member of the West Virginia University Health System, clinically evaluating the impact of Steripath in reducing false-positive blood culture results throughout the hospital.

Key Points: 
  • The WVU Medicine leadership have prioritized a strategic initiative to reduce blood culture contamination system-wide, which includes an assessment of the impact of Steripath.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.
  • Initial Specimen Diversion Device reduces blood culture contamination and vancomycin use in academic medical center.
  • Getting to zero: impact of a device to reduce blood culture contamination and false-positive central line-associated blood stream infections.

Magnolia Medical, MHA Solutions, and Healthcare Providers Insurance Company Enter into an Exclusive, Endorsed Agreement for the Steripath® Initial Specimen Diversion Device®

Retrieved on: 
Wednesday, December 15, 2021
Well, Solution, Hospital, ISDT, Board of directors, FDA, Invention, Intellectual property, Board, Awareness, Ownership, Meridian Medical Technologies Inc., Magnolia, Sepsis, CEO, Research, Patient, Vancomycin, Knowledge, NOAAS Bell M. Shimada (R 227), Patent, Health care, Blood culture, Infection, Collection, Multimedia, Patient safety, MHA, Analysis, Risk management, Technology, View, Medical device, Pharmaceutical industry, Vaccine, Silviculture

Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.

Key Points: 
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.
  • HPIC is a reciprocal insurance company providing professional liability and worker's compensation insurance to healthcare providers and healthcare systems.
  • Rupp ME, Cavalieri RJ, Marolf C, Lyden E. Reduction in blood culture contamination through use of Initial Specimen Diversion Device.
  • Tompkins LS, Madison A, Schaffner T, Tran J, Ang P. Eliminating blood culture contamination with an Initial-Specimen Diversion Device.

Magnolia Medical Further Strengthens Executive Management Team with the Addition of Silicon Valley Financial Leader, Patrick O'Malley, as Chief Financial Officer

Retrieved on: 
Thursday, October 28, 2021
Meridian Medical Technologies Inc., Infection, Research, Technology, Seagate Technology, Seagate, O'Malley, Invention, NASDAQ, FDA, Sepsis, Blood culture, NYSE, Collection, Patent, CEO, ISDT, Growth, Multimedia, Christopher O'Malley, Intellectual property, AVYA, Medical device, Management, Pharmaceutical industry

Before joining Magnolia, O'Malley was Chief Financial Officer of Avaya (NYSE: AVYA) where he led the financial restructuring of the company's $4 billion capital structure before taking the company public on the NYSE.

Key Points: 
  • Before joining Magnolia, O'Malley was Chief Financial Officer of Avaya (NYSE: AVYA) where he led the financial restructuring of the company's $4 billion capital structure before taking the company public on the NYSE.
  • Prior to Avaya, O'Malley was Chief Financial Officer at Seagate Technology (NASDAQ: STX).
  • During his tenure as an executive, Seagate's public market value grew from $1 billion to over $12 billion.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.

Magnolia Medical Appoints Industry Veteran, Joseph Bishop, as the Senior Vice President of Operations and Product Development

Retrieved on: 
Tuesday, October 26, 2021
Meridian Medical Technologies Inc., Infection, Engineering, Technology, Hypertension, Invention, Patient, FDA, Sepsis, Blood culture, Bishop, Quality assurance, Senior, Strategic planning, Collection, Patent, Magnolia, CEO, ISDT, COO, Regulatory affairs, Development, Acquisition, D, Medical device, Management, Pharmaceutical industry

Mr. Bishop brings extensive and diverse medical device experience to Magnolia Medical.

Key Points: 
  • Mr. Bishop brings extensive and diverse medical device experience to Magnolia Medical.
  • Prior to joining Magnolia Medical, Bishop served as Vice President of Operations and R&D for Vascular Dynamics, an emerging growth medical technology company focused on innovative implantable devices to address the unmet need for patients with uncontrolled hypertension.
  • Prior, Bishop was a member of the Executive Leadership Team at Suneva Medical Corporation where he was accountable for strategy and execution of all Operations and Research and Development activities.
  • In his role as a member of the Magnolia Medical executive leadership team, Bishop is responsible for the Operations, Product Development, Quality Assurance, and Regulatory Affairs teams.

Magnolia Medical Awarded National GPO and Value-Based Contract from Premier Inc. for Steripath® Initial Specimen Diversion Device®

Retrieved on: 
Tuesday, October 12, 2021
Patent, Infection, Clinical collaboration, Invention, Multimedia, Collection, FDA, Magnolia, Hospital, Sepsis, ISDT, GPO, CCO, Premier, Inc., Research, Blood culture, Organization, Medical device, Pharmaceutical industry

Effective December 1, 2021, the new agreement enables Premier members to take advantage of pricing and terms pre-negotiated by Premier for the Steripath and Steripath Micro Initial Specimen Diversion Device platforms.

Key Points: 
  • Effective December 1, 2021, the new agreement enables Premier members to take advantage of pricing and terms pre-negotiated by Premier for the Steripath and Steripath Micro Initial Specimen Diversion Device platforms.
  • Premier members who enroll in the Value-Based Tier of the contract are guaranteed a sustained reduction in blood culture contamination of 50% or greater for as long as they use Steripath or their money back.2
    "We are thrilled to have been awarded a national contract by Premier.
  • Now Steripath is available for Premier members to significantly reduce blood culture contamination and false-positive CLABSIs at a time when the need has never been greater," said Bob Gerberich, CCO of Magnolia Medical Technologies.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.